|
Status |
Public on Sep 28, 2016 |
Title |
The BET bromodomain inhibitor CPI203 improves lenalidomide activity in in vitro and in vivo models of multiple myeloma by synergistic blockade of Ikaros and c-Myc signaling |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Multiple myeloma (MM) cells were treated with the BET inhibitor CPI203 alone and in combination with lenalidomide plus dexamethasone in vitro and in vivo (mouse xenograft). We used microarrays to uncover the mechanisms underlying CPI-203 activity in MM, alone and in combination with lenalidomide plus dexamethasone (combo).
|
|
|
Overall design |
Global RNA expression was done in three MM cell lines treated in vitro with the BET inhibitor alone or with the combo for 6h.
|
|
|
Contributor(s) |
Diaz T, Pérez-Galán P, Roué G, Fernandez de Larrea C |
Citation(s) |
28751557 |
Submission date |
Sep 27, 2016 |
Last update date |
Mar 21, 2019 |
Contact name |
Patricia Pérez-Galán |
E-mail(s) |
pperez@clinic.cat
|
Phone |
932275400
|
Organization name |
IDIBAPS
|
Department |
Hemato-oncology
|
Street address |
Centre Esther Koplowitz, Hemato-oncology dept, Rosello 149-153, 2nd floor
|
City |
Barcelona |
State/province |
Barcelona |
ZIP/Postal code |
08036 |
Country |
Spain |
|
|
Platforms (1) |
GPL13667 |
[HG-U219] Affymetrix Human Genome U219 Array |
|
Samples (12)
|
|
Relations |
BioProject |
PRJNA344666 |